RedShift BioAnalytics nets $18 mn

Burlington, Massachusetts-based RedShift BioAnalytics Inc, a provider of analytical instrumentation for the research, development and manufacture of protein therapeutic drugs, has raised $18 million in funding.

Burlington, Massachusetts-based RedShift BioAnalytics Inc, a provider of analytical instrumentation for the research, development and manufacture of protein therapeutic drugs, has raised $18 million in funding. The investors included Waters Corporation. In addition to the funding, the company has named Julien Bradley as CEO.

Source: Press Release